Danai Georgia Topouza

Ms. Danai Georgia Topouza

Queen's University, Kingston, Canada
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAugusto Faria Andrade
Augusto Faria Andrade
AAAlva Annett
Alva Annett
EKElham Karimi
Elham Karimi
Danai Georgia TopouzaDanai Georgia Topouza
Danai Georgia Topouza
MRMorteza Rezanejad
Morteza Rezanejad
NJNada Jabado
Nada Jabado
Histone H3-mutant gliomas are deadly brain tumors characterized by a dysregulated epigenome and stalled differentiation. In contrast to the extensive datasets available on tumor cells, limited information exists on their tumor microenvironment (TME), particularly the immune infiltrate. Here, we characterize the immune TME of H3.3K27M and G34R/V-mutant gliomas, and multiple H3.3K27M mouse models, using transcriptomic, proteomic and spatial single-cell approaches. Resolution of immune lineages indicates high infiltration of H3-mutant gliomas with diverse myeloid populations, high-level expression of immune checkpoint markers, and scarce lymphoid cells, findings uniformly reproduced in all H3.3K27M mouse models tested. We show these myeloid populations communicate with H3-mutant cells, mediating immunosuppression and sustaining tumor formation and maintenance. Dual inhibition of myeloid cells and immune checkpoint pathways show significant therapeutic benefits in pre-clinical syngeneic mouse models. Our findings provide a valuable characterization of the TME of oncohistone-mutant gliomas, and insight into the means for modulating the myeloid infiltrate for the benefit of patients.

10 February 2022
Verified
Dataset
Closed access
KNKathleen Nevola
Kathleen Nevola
MSMarianne Sandin
Marianne Sandin
JGJamey Guess
Jamey Guess
SFSimon Forsberg
Simon Forsberg
CCChristoffer Cambronero
Christoffer Cambronero
KHKristian Persson Hodén
Kristian Persson Hodén

2 May 2022 in Occupational and Environmental Medicine
Verified
Journal Article
Closed access
PDF file
JRJennifer A Ritonja
Jennifer A Ritonja
KAKristan J Aronson
Kristan J Aronson
MLMichael Leung
Michael Leung
LFLisa Flaten
Lisa Flaten
Danai Georgia TopouzaDanai Georgia Topouza
Danai Georgia Topouza
PBParveen Bhatti
Parveen Bhatti
Objectives: Mechanisms underlying the carcinogenicity of night shift work remain uncertain. One compelling yet understudied cancer mechanism may involve altered DNA methylation in circadian genes due to melatonin secretion patterns. The objective of this study was to explore the relationship between melatonin secretion patterns and circadian gene methylation among day and night shift workers.Methods: Female healthcare employees (n=38 day workers, n=36 night shift workers) for whom we had urinary 6-sulfatoxymelatonin secretion data from a previous study were recontacted. New blood samples were collected and used to measure methylation levels at 1150 CpG loci across 22 circadian genes using the Illumina Infinium MethylationEPIC beadchip. Linear regression was used to examine the association between melatonin (acrophase and mesor) and M values for each CpG site (false discovery rate, q=0.2), while testing for effect modification by shift work status.Results: Among night shift workers, a higher mesor (24 hours of mean production of melatonin) was associated with increased methylation in the body ofRORA(q=0.02) and decreased methylation in the putative promoter region ofMTNR1A(q=0.03). Later acrophase (ie, time of peak concentration) was associated with increased methylation in the putative promoter region ofMTNR1A(q=0.20) and decreased methylation in the body ofPER3(q=0.20). No associations were identified among day workers.Conclusions: In conclusion, patterns in melatonin secretion were associated with differential circadian gene methylation among night shift workers. Melatonin and alteration of DNA methylation in circadian genes may be one pathway towards increased cancer risk, although larger-scale studies examining multiple time points are needed.

13 May 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JCJihoon Choi
Jihoon Choi
Danai Georgia TopouzaDanai Georgia Topouza
Danai Georgia Topouza
ATAnastasiya Tarnouskaya
Anastasiya Tarnouskaya
SNSean Nesdoly
Sean Nesdoly
MKMadhuri Koti
Madhuri Koti
QDQing Ling Duan
Qing Ling Duan
Background: A major impediment in the treatment of ovarian cancer is the relapse of chemotherapy-resistant tumors, which occurs in approximately 25% of patients. A better understanding of the biological mechanisms underlying chemotherapy resistance will improve treatment efficacy through genetic testing and novel therapies. Methods: Using data from high-grade serous ovarian carcinoma (HGSOC) patients in the Cancer Genome Atlas (TCGA), we classified those who remained progression-free for 12 months following platinum-taxane combination chemotherapy as “chemo-sensitive” (N = 160) and those who had recurrence within 6 months as “chemo-resistant” (N = 110). Univariate and multivariate analysis of expression microarray data were used to identify differentially expressed genes and co-expression gene networks associated with chemotherapy response. Moreover, we integrated genomics data to determine expression quantitative trait loci (eQTL). Results: Differential expression of the Valosin-containing protein (VCP) gene and five co-expression gene networks were significantly associated with chemotherapy response in HGSOC. VCP and the most significant co-expression network module contribute to protein processing in the endoplasmic reticulum, which has been implicated in chemotherapy response. Both univariate and multivariate analysis findings were successfully replicated in an independent ovarian cancer cohort. Furthermore, we identified 192 cis-eQTLs associated with the expression of network genes and 4 cis-eQTLs associated with BRCA2 expression. Conclusion: This study implicates both known and novel genes as well as biological processes underlying response to platinum-taxane-based chemotherapy among HGSOC patients.

Verified
Journal Article
Open access
PDF file
Danai Georgia TopouzaDanai Georgia Topouza
Danai Georgia Topouza
JCJihoon Choi
Jihoon Choi
SNSean Nesdoly
Sean Nesdoly
ATAnastasiya Tarnouskaya
Anastasiya Tarnouskaya
CNChristopher Nicol
Christopher Nicol
QDQing Ling Duan
Qing Ling Duan
High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecologic cancer, in part due to resistance to platinum-based chemotherapy reported among 20% of patients. This study aims to generate novel hypotheses of the biological mechanisms underlying chemotherapy resistance, which remain poorly understood. Differential expression analyses of mRNA- and microRNA-sequencing data from HGSOC patients of The Cancer Genome Atlas identified 21 microRNAs associated with angiogenesis and 196 mRNAs enriched for adaptive immunity and translation. Coexpression network analysis identified three microRNA networks associated with chemotherapy response enriched for lipoprotein transport and oncogenic pathways, as well as two mRNA networks enriched for ubiquitination and lipid metabolism. These network modules were replicated in two independent ovarian cancer cohorts. Moreover, integrative analyses of the mRNA/microRNA sequencing and single-nucleotide polymorphisms (SNPs) revealed potential regulation of significant mRNA transcripts by microRNAs and SNPs (expression quantitative trait loci). Thus, we report novel transcriptional networks and biological pathways associated with resistance to platinum-based chemotherapy in HGSOC patients. These results expand our understanding of the effector networks and regulators of chemotherapy response, which will help to improve the management of ovarian cancer.

1 July 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
AZAmanda M. Zacharias
Amanda M. Zacharias
COCiara D. O’cOnnor
Ciara D. O’cOnnor
Danai Georgia TopouzaDanai Georgia Topouza
Danai Georgia Topouza
ZFZhi Yi Fang
Zhi Yi Fang
HGHelia Ghazinejad
Helia Ghazinejad
NGNader Ghasemlou
Nader Ghasemlou
Biological rhythms control gene expression, but effects on central nervous system (CNS) cells and structures remain poorly defined. While circadian (24-hour) rhythms are most studied, many genes have periods of greater and less than 24-hours; these fluctuations can be both site- and cell-specific. Identifying patterns of gene rhythmicity across the CNS is necessary for both the study of chronobiology and to make sense of data obtained in the laboratory. We now identify cycling mRNAs, miRNAs, gene networks and mRNA-miRNA co-expression pairs in the cortex, hypothalamus, and corpus striatum of male C57BL/6J mice using high-dimensional datasets. A searchable catalogue (https://www.ghasemloulab.ca/chronoCNS) helps refine the analysis of cellular and molecular rhythmicity across the CNS (using the liver as a control). Immunofluorescence confirms the rhythmicity of key targets across cells in these structures, with strong cycling signatures in resting oligodendrocytes. Our study sheds light on the contribution of diurnal, ultradian, and infradian rhythms and mRNA-miRNA interactions to CNS function.